Paper36958796
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM and 43 others. Ann Rheum Dis, 2023. Cited by 107 papers, by iCite.
Cite this record
ConductScience Library. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Papers, record 36958796. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36958796
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
- PubMed
- Publication types
- Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, Equivalence Trial
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Azathioprine | Major topic |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Major topic |
| Humans | |
| Rituximab | |
| Immunosuppressive Agents | |
| Recurrence | |
| Remission Induction | |
| Treatment Outcome | |
| Cyclophosphamide | |
| Antibodies, Antineutrophil Cytoplasmic |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | PubMed | ||
| 19706 | Versus Arthritis | United Kingdom | PubMed | PubMed | |
| U54 AR057319 | NIAMS NIH HHS | United States | U54AR057319 | PubMed and NIH | NIH RePORTER |
| U54 RR019497 | NCRR NIH HHS | United States | U54RR019497 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01697267 | Rituximab Vasculitis Maintenance Study | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 37523707 | In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo. | https://conductscience.org/library/papers/37523707 |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15673801 | Etanercept plus standard therapy for Wegener's granulomatosis. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15673801 | PubMed |
| 2 | 35317410 | Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. | Lancet Rheumatol | 2022 | https://conductscience.org/library/papers/35317410 | PubMed |
| 3 | 35714496 | Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. | J Autoimmun | 2022 | https://conductscience.org/library/papers/35714496 | PubMed |
| 4 | 35115385 | Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. | RMD Open | 2022 | https://conductscience.org/library/papers/35115385 | PubMed |
| 5 | 21953279 | Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. | Arthritis Rheum | 2012 | https://conductscience.org/library/papers/21953279 | PubMed |
| 6 | 34781162 | Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. | J Autoimmun | 2021 | https://conductscience.org/library/papers/34781162 | PubMed |
| 7 | 34977602 | Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. | Lancet Rheumatol | 2022 | https://conductscience.org/library/papers/34977602 | PubMed |
| 8 | 23045170 | 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. | Arthritis Rheum | 2013 | https://conductscience.org/library/papers/23045170 | PubMed |
| 9 | 23902481 | Efficacy of remission-induction regimens for ANCA-associated vasculitis. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23902481 | PubMed |
| 10 | 20647199 | Rituximab versus cyclophosphamide for ANCA-associated vasculitis. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20647199 | PubMed |
| 11 | 19454608 | Assessment of damage in vasculitis: expert ratings of damage. | Rheumatology (Oxford) | 2009 | https://conductscience.org/library/papers/19454608 | PubMed |
| 12 | 33141217 | Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/33141217 | PubMed |
| 13 | 32053298 | Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32053298 | PubMed |
| 14 | 19451574 | Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. | Ann Intern Med | 2009 | https://conductscience.org/library/papers/19451574 | PubMed |
| 15 | 12840090 | A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12840090 | PubMed |
| 16 | 28270229 | Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. | Trials | 2017 | https://conductscience.org/library/papers/28270229 | PubMed |
| 17 | 22729997 | Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. | Arthritis Rheum | 2012 | https://conductscience.org/library/papers/22729997 | PubMed |
| 18 | 25372085 | Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25372085 | PubMed |
| 19 | 11318006 | A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). | Arthritis Rheum | 2001 | https://conductscience.org/library/papers/11318006 | PubMed |
| 20 | 4157287 | Long-term follow-up study of periarteritis nodosa. | Am J Med | 1967 | https://conductscience.org/library/papers/4157287 | PubMed |
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42955334 | Immunosuppressive management of ANCA-associated glomerulonephritis in children. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42955334 | PubMed |
| 42851467 | Targeting tissue immune memory in chronic-remitting autoimmune kidney diseases: current concepts and future therapies. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42851467 | PubMed |
| 42761370 | Clinical scenarios of suboptimal response to rituximab in relapsing ANCA-associated vasculitis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42761370 | PubMed |
| 42743142 | Clinical outcomes after relapse during rituximab-based maintenance in ANCA-associated vasculitis: A single-center retrospective cohort study. | PLoS One | 2026 | https://conductscience.org/library/papers/42743142 | PubMed |
| 42720689 | Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42720689 | PubMed |
| 42649433 | From ANCA-mediated vascular injury to coronary microvascular and myocardial involvement in granulomatosis with polyangiitis: an immunocardiology perspective. | Rheumatol Int | 2026 | https://conductscience.org/library/papers/42649433 | PubMed |
| 42614134 | Immunoglobulin replacement therapy in antineutrophil cytoplasmic antibody-associated vasculitis with rituximab-associated hypogammaglobulinemia: infection outcomes and disease course in a retrospective cohort. | Front Nephrol | 2026 | https://conductscience.org/library/papers/42614134 | PubMed |
| 42553115 | BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42553115 | PubMed |
| 42532981 | Biosimilar Rituximab in ANCA-Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study. | ACR Open Rheumatol | 2026 | https://conductscience.org/library/papers/42532981 | PubMed |
| 42512795 | Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42512795 | PubMed |
| 42482905 | ANCA-associated vasculitis: a phase-oriented therapeutic framework from immunopathology to precision treatment. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42482905 | PubMed |
| 42391608 | Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis. | Rheumatology (Oxford) | 2026 | https://conductscience.org/library/papers/42391608 | PubMed |
| 42342286 | No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. | RMD Open | 2026 | https://conductscience.org/library/papers/42342286 | PubMed |
| 41866438 | Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA. | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/41866438 | PubMed |
| 41803922 | Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS). | Arthritis Res Ther | 2026 | https://conductscience.org/library/papers/41803922 | PubMed |
| 41675526 | Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines. | Can J Kidney Health Dis | 2026 | https://conductscience.org/library/papers/41675526 | PubMed |
| 41439239 | Shifting Sands or ANCA-ed in Place? The Epidemiology of ANCA-Associated Vasculitis over 2 Decades at a Large Tertiary Centre. | Glomerular Dis | 2026 | https://conductscience.org/library/papers/41439239 | PubMed |
| 41412975 | Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab. | Arthritis Rheumatol | 2026 | https://conductscience.org/library/papers/41412975 | PubMed |
| 41345710 | Maternal-fetal outcomes and therapeutic strategies in pregnancies complicated by Takayasu arteritis: a comprehensive analysis. | Arthritis Res Ther | 2025 | https://conductscience.org/library/papers/41345710 | PubMed |
| 41324350 | Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement. | Am J Respir Crit Care Med | 2025 | https://conductscience.org/library/papers/41324350 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CMPK1 | 51727 | PubTator's text mining | https://conductscience.org/library/genes/51727 | NCBI Gene |
| MPO | 4353 | PubTator's text mining | https://conductscience.org/library/genes/4353 | NCBI Gene |
| PRTN3 | 5657 | PubTator's text mining | https://conductscience.org/library/genes/5657 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1201576 | ChEMBL |
| AZATHIOPRINE | CHEMBL1542 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1542 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36958796
GET https://conductscience.org/api/papers/v1/36958796/authors?page=2